Maintenance Notice (4:30 AM - 11:00 AM December 21, 2024): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.197
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 78351-75-4 | Product Number: C2884
1-(3-Chloroanilino)-4-phenylphthalazine
×
![]()
×
Purity: >98.0%(GC)
Synonyms:
- MY-5445
- 1-(3-Chlorophenyl)amino-4-phenylphthalazine
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 20MG |
57,00 €
|
1 | 22 |
|
| 100MG |
223,00 €
|
1 | 30 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | C2884 |
| Purity / Analysis Method | >98.0%(GC) |
| Molecular Formula / Molecular Weight | C__2__0H__1__4ClN__3 = 331.80 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| CAS RN | 78351-75-4 |
| PubChem Substance ID | 253661527 |
| MDL Number | MFCD00209838 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(GC) | min. 98.0 % |
| NMR | confirm to structure |
Properties (reference)
GHS
Related Laws:
Transport Information:
| HS Number | 2933998090 |
Application
MY-5445: A Specific Inhibitor of Cyclic GMP Phosphodiesterase Type 5 (PDE5)
1-(3-Chloroanilino)-4-phenylphthalazine (MY-5445) is a specific inhibitor of cyclic GMP (cGMP) phosphodiesterase type 5 (PDE5). MY-5445 inhibits platelet aggregation by increasing cGMP content.
References
Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation
M. Hagiwara, T. Endo, T. Kanayama, H. Hidaka, J. Pharmacol. Exp. Ther. 1984, 228, 467.
Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine
J. E. Souness, R. Brazdil, B. K. Diocee, R. Jordan, Br. J. Pharmacol. 1989, 98, 725.
Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin
Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.